228 related articles for article (PubMed ID: 21677003)
21. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement.
Smith V; Piette Y; van Praet JT; Decuman S; Deschepper E; Elewaut D; De Keyser F
J Rheumatol; 2013 Jan; 40(1):52-7. PubMed ID: 23118116
[TBL] [Abstract][Full Text] [Related]
22. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
Heiligenhaus A; Miserocchi E; Heinz C; Gerloni V; Kotaniemi K
Rheumatology (Oxford); 2011 Aug; 50(8):1390-4. PubMed ID: 21378109
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.
Payet S; Soubrier M; Perrodeau E; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Gottenberg JE; Mariette X
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1289-95. PubMed ID: 25299001
[TBL] [Abstract][Full Text] [Related]
24. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.
Roubaud-Baudron C; Pagnoux C; Méaux-Ruault N; Grasland A; Zoulim A; LE Guen J; Prud'homme A; Bienvenu B; de Menthon M; Camps S; LE Guern V; Aouba A; Cohen P; Mouthon L; Guillevin L;
J Rheumatol; 2012 Jan; 39(1):125-30. PubMed ID: 22089465
[TBL] [Abstract][Full Text] [Related]
25. A pilot trial of rituximab in the treatment of patients with dermatomyositis.
Chung L; Genovese MC; Fiorentino DF
Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943
[TBL] [Abstract][Full Text] [Related]
26. Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.
Sener S; Cam V; Ozen S; Batu ED
Clin Rheumatol; 2024 Feb; 43(2):591-602. PubMed ID: 37582998
[TBL] [Abstract][Full Text] [Related]
27. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.
Thomas L; Canoui-Poitrine F; Gottenberg JE; Economu-Dubosc A; Medkour F; Chevalier X; Bastuji-Garin S; Le Louët H; Farrenq V; Claudepierre P
J Rheumatol; 2012 May; 39(5):893-8. PubMed ID: 22505694
[TBL] [Abstract][Full Text] [Related]
28. The lung is involved in juvenile dermatomyositis.
Pouessel G; Deschildre A; Le Bourgeois M; Cuisset JM; Catteau B; Karila C; Nève V; Thumerelle C; Quartier P; Tillie-Leblond I
Pediatr Pulmonol; 2013 Oct; 48(10):1016-25. PubMed ID: 23281200
[TBL] [Abstract][Full Text] [Related]
29. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
Levine TD
Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
[TBL] [Abstract][Full Text] [Related]
30. Juvenile dermatomyositis in north India.
Singh S; Kumar L; Shankar KR
Indian Pediatr; 1997 Mar; 34(3):193-8. PubMed ID: 9282485
[TBL] [Abstract][Full Text] [Related]
31. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV; Reed AM; Aggarwal R; Rider LG; Ascherman DP; Levesque MC; Barohn RJ; Feldman BM; Harris-Love MO; Koontz DC; Fertig N; Kelley SS; Pryber SL; Miller FW; Rockette HE;
Arthritis Rheum; 2013 Feb; 65(2):314-24. PubMed ID: 23124935
[TBL] [Abstract][Full Text] [Related]
32. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
33. Successful use of rituximab in recalcitrant skin predominant dermatomyositis.
Joshi N; Nautiyal A; Davies PG
J Clin Rheumatol; 2011 Mar; 17(2):111-2. PubMed ID: 21364354
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.
Kasperkiewicz M; Eming R; Behzad M; Hunzelmann N; Meurer M; Schulze-Koops H; von Wussow P; Hertl M; Zillikens D; Freivogel K; Dörner T; Schmidt E
J Dtsch Dermatol Ges; 2012 Oct; 10(10):727-32. PubMed ID: 22577946
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of rituximab treatment in Indian pemphigus patients.
Kanwar AJ; Tsuruta D; Vinay K; Koga H; Ishii N; Dainichi T; Hashimoto T
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e17-23. PubMed ID: 22176540
[TBL] [Abstract][Full Text] [Related]
36. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
38. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
[TBL] [Abstract][Full Text] [Related]
39. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
Marhaug G; Shah V; Shroff R; Varsani H; Wedderburn LR; Pilkington CA; Brogan PA
Rheumatology (Oxford); 2008 Jul; 47(7):1031-7. PubMed ID: 18448482
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.
Mekinian A; Ravaud P; Larroche C; Hachulla E; Gombert B; Blanchard-Delaunay C; Cantagrel A; Fain O; Sibilia J; Gottenberg JE; Mariette X;
Clin Exp Rheumatol; 2012; 30(2):208-12. PubMed ID: 22341206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
